Finanztrends
Deine Einschätzung
Was spricht für und gegen Genetic Technologies Ltd. in den nächsten Jahren?
Pro
?
U****************
?
A****************
?
M****
Kontra
?
W******* i* V********
?
L*********** I********** f** d** n******* J****
?
M************
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Genetic Technologies Ltd. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Genetic Technologies Ltd. | - | - | - | - | - | - | - |
| Invion Ltd | 0,00 % | 0,00 % | 0,00 % | -47,50 % | -47,50 % | 2000,00 % | 366,67 % |
| Immutep LTD ADR | 0,60 % | -2,98 % | -12,37 % | -78,41 % | -87,46 % | -83,11 % | -89,62 % |
| Alterity Therapeutics Ltd. ADR | - | -2,14 % | -19,38 % | -2,53 % | 47,58 % | -2,53 % | -67,32 % |
Kommentare
News
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
Key Points
- Interested in Black Diamond Therapeutics, Inc.? Here are five stocks we like better.
- Silevertinib showed encouraging Phase 2 lung cancer data, including a 60% objective response
Pelthos Therapeutics Q1 Earnings Call Highlights
Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch